期刊
BIOMATERIALS
卷 156, 期 -, 页码 217-237出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2017.10.024
关键词
Nanomedicine; Cancer theranostics; Tumor microenvironment; Drug delivery
资金
- Vanier Canada Graduate Scholarship
- Terry Fox Research Institute [TFRI 1075]
- Canadian Institutes of Health Research [CIHR PJT148740, CIHR - FDN 154326]
- Natural Sciences and Engineering Research Council of Canada [48907]
- Canadian Cancer Society Research Institute [CCSRI 704718]
- Prostate Cancer Canada [PCC MOVEMBER D201507]
- Canada Foundation for Innovation (CFI) [21765]
- Princess Margaret Cancer Foundation (PMCF COMM) [215, PMCF IAF 88410817286]
Despite rapid advancements in the field of nanotechnology, there is mounting frustration in the scientific community regarding the translational impact of nanomedicine. Modest therapeutic performance of FDA-approved nanomedicines combined with multiple disappointing clinical trials (such as phase III HEAT trial) have raised questions about the future of nanomedicine. Encouraging breakthroughs, however, have been made in the last few years towards the development of new classes of nanoparticles that can respond to tumor microenvironmental conditions and successfully deliver therapeutic agents to cancer cells. Concurrently, a great deal of effort has also been devoted to alter various parameters of tumor pathophysiology to pre-treat tumors before nanoparticles are administered. Such 'priming' treatments improve access of the systemically administered agents to the tumor and promote drug penetration into the deeper layers of tumor tissue. This review will highlight recent advances in cancer nanomedicine exploiting both nanoparticle design and tumor microenvironment modification; and provide a critical perspective on the future development of nanomedicine delivery in oncology. (C) 2017 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据